Plant Secondary Metabolites As Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Jan 17

PMID 29337925

Citations 205

Authors

Ana M L Seca

Diana C G A Pinto

Affiliations

Soon will be listed here.

Abstract

Cancer is a multistage process resulting in an uncontrolled and abrupt division of cells and is one of the leading causes of mortality. The cases reported and the predictions for the near future are unthinkable. Food and Drug Administration data showed that 40% of the approved molecules are natural compounds or inspired by them, from which, 74% are used in anticancer therapy. In fact, natural products are viewed as more biologically friendly, that is less toxic to normal cells. In this review, the most recent and successful cases of secondary metabolites, including alkaloid, diterpene, triterpene and polyphenolic type compounds, with great anticancer potential are discussed. Focusing on the ones that are in clinical trial development or already used in anticancer therapy, therefore successful cases such as paclitaxel and homoharringtonine (in clinical use), curcumin and ingenol mebutate (in clinical trials) will be addressed. Each compound's natural source, the most important steps in their discovery, their therapeutic targets, as well as the main structural modifications that can improve anticancer properties will be discussed in order to show the role of plants as a source of effective and safe anticancer drugs.

Citing Articles

Plant-derived terpenoids modulating cancer cell metabolism and cross-linked signaling pathways: an updated reviews.

Pandey P, Verma M, Sanghvi G, R R, Joshi K, V K Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40019530 DOI: 10.1007/s00210-025-03937-y.

In-vitro antioxidant and anti-proliferative activity of aerial parts of Senecio Laetus Edgew on breast cancer (MCF-7) and colon carcinoma (HCT116) cell lines.

Wadoo R, Ali T, Jan I, Mir S, Amin A, Qadri R BMC Complement Med Ther. 2025; 25(1):45.

PMID: 39934801 PMC: 11816538. DOI: 10.1186/s12906-025-04789-y.

Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions.

Shafombabi N, Knott M, Kapewangolo P, Sharifi-Rad J, Calina D Med Oncol. 2025; 42(3):69.

PMID: 39921761 DOI: 10.1007/s12032-025-02615-6.

Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases.

Anwer E, Ajagbe M, Sherif M, Musaibah A, Mahmoud S, ElBanbi A Biomedicines. 2025; 13(1).

PMID: 39857684 PMC: 11762448. DOI: 10.3390/biomedicines13010100.

Phytochemicals in Breast Cancer Prevention and Treatment: A Comprehensive Review.

Wali A, Pillai J, Talath S, Shivappa P, Sridhar S, El-Tanani M Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852145 PMC: 11764082. DOI: 10.3390/cimb47010030.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Guo Z . The modification of natural products for medical use. Acta Pharm Sin B. 2017; 7(2):119-136. PMC: 5343118. DOI: 10.1016/j.apsb.2016.06.003. View

Howat S, Park B, Oh I, Jin Y, Lee E, Loake G . Paclitaxel: biosynthesis, production and future prospects. N Biotechnol. 2014; 31(3):242-5. DOI: 10.1016/j.nbt.2014.02.010. View

Benhadji K, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne S . Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008; 99(11):1808-15. PMC: 2600681. DOI: 10.1038/sj.bjc.6604642. View

Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Russo L . Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015; 10(5):1615-1623. PMC: 4665301. DOI: 10.3892/etm.2015.2749. View

Shankar E, Zhang A, Franco D, Gupta S . Betulinic Acid-Mediated Apoptosis in Human Prostate Cancer Cells Involves p53 and Nuclear Factor-Kappa B (NF-κB) Pathways. Molecules. 2017; 22(2). PMC: 5832059. DOI: 10.3390/molecules22020264. View

Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta D . Paclitaxel: What has been done and the challenges remain ahead. Int J Pharm. 2017; 526(1-2):474-495. DOI: 10.1016/j.ijpharm.2017.05.016. View

Kocaadam B, Sanlier N . Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2015; 57(13):2889-2895. DOI: 10.1080/10408398.2015.1077195. View

Pasic I, Lipton J . Current approach to the treatment of chronic myeloid leukaemia. Leuk Res. 2017; 55:65-78. DOI: 10.1016/j.leukres.2017.01.005. View

10.

Ekor M . The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 4:177. PMC: 3887317. DOI: 10.3389/fphar.2013.00177. View

11.

Beres T, Dragull K, Pospisil J, Tarkowska D, Dancak M, Biba O . Quantitative Analysis of Ingenol in Euphorbia species via Validated Isotope Dilution Ultra-high Performance Liquid Chromatography Tandem Mass Spectrometry. Phytochem Anal. 2017; 29(1):23-29. DOI: 10.1002/pca.2711. View

12.

Gheorgheosu D, Duicu O, Dehelean C, Soica C, Muntean D . Betulinic acid as a potent and complex antitumor phytochemical: a minireview. Anticancer Agents Med Chem. 2014; 14(7):936-45. DOI: 10.2174/1871520614666140223192148. View

13.

Diorio C, Salena K, Ladas E, Lam C, Afungcwhi G, Njuguna F . Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review. Pediatr Blood Cancer. 2017; 64(9). DOI: 10.1002/pbc.26501. View

14.

Borges G, Rego D, Assad D, Coletta R, De Luca Canto G, Guerra E . In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review. J Oral Pathol Med. 2016; 46(1):3-20. DOI: 10.1111/jop.12455. View

15.

Pisha E, Chai H, Lee I, Chagwedera T, Farnsworth N, Cordell G . Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995; 1(10):1046-51. DOI: 10.1038/nm1095-1046. View

16.

Kumar G, Mittal S, Sak K, Tuli H . Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives. Life Sci. 2016; 148:313-28. DOI: 10.1016/j.lfs.2016.02.022. View

17.

Weaver B . How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014; 25(18):2677-81. PMC: 4161504. DOI: 10.1091/mbc.E14-04-0916. View

18.

Haris P, Mary V, Aparna P, Dileep K, Sudarsanakumar C . A comprehensive approach to ascertain the binding mode of curcumin with DNA. Spectrochim Acta A Mol Biomol Spectrosc. 2016; 175:155-163. DOI: 10.1016/j.saa.2016.11.049. View

19.

Klippstein R, Bansal S, Al-Jamal K . Doxorubicin enhances curcumin's cytotoxicity in human prostate cancer cells in vitro by enhancing its cellular uptake. Int J Pharm. 2016; 514(1):169-175. DOI: 10.1016/j.ijpharm.2016.08.003. View

20.

Ehrlich A, Booher S, Becerra Y, Borris D, Figg W, Turner M . Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol. 2004; 50(4):533-40. DOI: 10.1016/j.jaad.2003.09.018. View